PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.68
−1.05%Nov 3, 2026, 13:00 UTC
Phathom Pharmaceuticals, Inc. announced that eligible commercially insured patients may now pay as little as $0 for VOQUEZNA tablets exclusively through BlinkRx.
Source:Oct 29, 2026, 13:36 UTC
Phathom Pharmaceuticals reported quarterly earnings of $0.04 per share, compared with a loss of $0.15 per share a year earlier.
Source:Oct 29, 2026, 11:00 UTC
Phathom Pharmaceuticals, Inc. reported third-quarter 2026 net revenues of $84.7 million, up 71% year over year.
Source:Oct 26, 2026, 08:00 UTC
The U.S. Food and Drug Administration established a public docket to solicit comments on legal and regulatory questions raised in BDR Pharmaceuticals International’s litigation over the agency’s rejection of its abbreviated new drug application referencing VOQUEZNA.
Source:Oct 23, 2026, 08:00 UTC
BDR Pharmaceuticals International filed suit against the U.S. Food and Drug Administration and related federal defendants, challenging the FDA’s alleged refusal to receive an ANDA referencing Phathom Pharmaceuticals’ VOQUEZNA application and its application of the GAIN Act to the drug’s exclusivity.
Source:Oct 8, 2026, 12:00 UTC
Phathom Pharmaceuticals announced that it will present three analyses of VOQUEZNA at the American College of Gastroenterology 2026 Annual Scientific Meeting, covering real-world patient characteristics, efficacy across BMI subgroups and cost-effectiveness in erosive esophagitis.
Source:Sep 29, 2026, 12:00 UTC
Phathom Pharmaceuticals initiated patient screening in the registrational Phase 3 pHalcon-NERD-302 study evaluating as-needed VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive GERD.
Source:Sep 9, 2026, 15:48 UTC
Phathom Pharmaceuticals presented at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, highlighting rapid revenue growth and its first quarterly operating profit excluding stock-based compensation.
Source:Jul 31, 2026, 14:07 UTC
SueWallSt notified investors of potential securities claims involving Phathom Pharmaceuticals, related to the company's full-year revenue guidance.
Source:Jul 30, 2026, 10:59 UTC
Phathom Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.
Source:Jun 23, 2026, 11:59 UTC
Phathom Pharmaceuticals completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA (vonoprazan) for eosinophilic esophagitis.
Source: